Dr. Nardo, on his 1boringoldman blog, recaps his letter to the FDA concerning his findings after reviewing the research data on the new antidepressant Brintellix (Vortioxetine). “Takeda and Lundbeck had gone all out and to a lot of expense trying for this (cognitive boost) indication [6 cognition-specific clinical trials, bringing a lot of big KOL guns to the IOM workshop and earlier hearing, etc] . . . But it just wasn’t in the data, and that’s what the FDA is there to evaluate. So good on them. They did the right thing after all.”
© 2024 Mad in America Foundation